Medherant has developed its own novel pressure sensitive adhesive. The drug to be delivered is mixed with the adhesive. This proprietary delivery system was well-tolerated in a Phase I clinical study.
In addition to developing its own transdermal and topical products, Medherant is collaborating with third parties to formulate their drugs for transdermal delivery using its TEPI technology. In the future, Medherant expects to receive milestone payments and/or licence revenues for products utilising its technology.
Medherant has secured funding from Mercia Fund Management and private investors.